Russia's public procurement of drugs posts growth this year

8 December 2020

Public procurements of drugs in Russia for the first three quarters of the current year amounted to 464 billion roubles ($6.27 billion), which is 10% more than a year ago, according to a recent report, published by the local analytics agency DSM Group.

Biocad, a local drugmaker, became leader in this segment, as its overall sales amounted to 24.3 billion roubles.

At the same time, Germany’s Merck KGaA (MRK: DE) and the USA’s Johnson & Johnson (NYSE: JNJ) were the second and third largest players in the market with sales of 23.1 billion roubles and 21.2 billion roubles, respectively. In the case of Merck, the growth of its Russian sales this year was almost a record compared to 2019, as they grew by nearly 39%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK